Nippon Shinyaku Co., Ltd.

4516

JP3717600005

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
4,335 ^JPY	+0.65%		+3.09%	-13.23%

Apr. 10	Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy	MT
Mar. 18	Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100	CI

Nippon Shinyaku Co., Ltd.(TSE:4516) added to S&P Japan Mid Cap 100

December 23, 2019 at 12:00 am EST

Latest news about Nippon Shinyaku Co., Ltd.

Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy	Apr. 10	MT
Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100	Mar. 17	CI
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	Feb. 09	MT
Jefferies Adjusts Nippon Shinyaku’s Price Target to 6,900 Yen From 6,700 Yen, Keeps at Buy	23-08-14	MT
Nippon Shinyaku Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2023	23-08-10	CI
Jefferies Adjusts Nippon Shinyaku's Price Target to 6,700 Yen From 7,700 Yen, Keeps at Buy	23-07-24	MT
Jefferies Upgrades Nippon Shinyaku to Buy From Hold, Adjusts Price Target to 7,700 Yen From 6,400 Yen	23-06-02	MT
Nippon Shinyaku Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-11	CI
Jefferies Adjusts Nippon Shinyaku's Price Target to 6,400 Yen From 7,300 Yen, Keeps at Hold	23-03-10	MT
Capricor Therapeutics Signs Commercialization, Distribution Deal With Nippon Shinyaku in Japan	23-02-16	MT
Capricor Therapeutics, Nippon Shinyaku Enter Marketing Deal for Duchenne Muscular Dystrophy Treatment in US	22-01-25	MT
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of Cap-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S	22-01-25	CI
Clinigen JV To Launch Viltepso Managed Access Program For Duchenne Muscular Dystrophy Patients	21-11-29	MT
Clinigen Group plc Signs Agreement with Nippon Shinyaku	21-11-29	CI
Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku	21-11-10	CI
Zogenix : Secures Orphan Drug Designation for Fintepla in Japan	21-08-26	MT
Nippon Shinyaku Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2021	21-08-10	CI
Nippon Shinyaku Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year 2021	21-08-10	CI
Nippon Shinyaku Co., Ltd. Announces Dividend for the Year Ended March 31, 2021, Scheduled Start of Payment June 30, 2021; Provides Dividend Guidance for the Second Quarter and Fiscal Year 2022	21-05-13	CI
Menarini Group and Nippon Shinyaku Co., Ltd. Enter into an Exclusive License Agreement to Develop and Commercialize Elzonris® (Tagraxofusp) in Japan	21-03-29	CI
Nippon Shinyaku Co. Ltd. Announces Consolidated Earnings Results for the Third Quarter Ended December 31, 2019; Provides Earnings Guidance for the Full Year Ending March 31, 2020	20-02-04	CI
Nippon Shinyaku Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2020	20-02-04	CI
Nippon Shinyaku Co., Ltd.(TSE:4516) added to S&P Japan Mid Cap 100	19-12-23	CI
Nippon Shinyaku Co. Ltd. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Earnings Guidance for the Full Year Ending March 31, 2020; Announces Dividend for the Second Quarter Ended September 30, 2019, Payable on December 5, 2019; Provides Dividend Guidance for the Full Year Ending March 31, 2020	19-11-05	CI
Nippon Shinyaku Co. Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2019; Provides Earnings Guidance for the First Half and Full Year of 2019	19-08-06	CI

Chart Nippon Shinyaku Co., Ltd.

Duration

Period

More charts

Nippon Shinyaku Co., Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceutical products and functional foodstuffs. The Company operates in two business segments. The Pharmaceutical segment is involved in the manufacture and sale of urinary system therapeutic agents, blood cancer therapeutic agents, pain, inflammation and allergic therapeutic agents, digestive system therapeutic agents, cardiovascular systems and metabolic therapeutic agents. The Functional Foodstuff segment involves in the manufacture and sale of health food materials, quality stability preservatives, protein preparation, spice and seasoning products. The Company is also involved in the business support business, non-life insurance agency business, as well as the provision of real estate leasing services.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Nippon Shinyaku Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4,335 JPY

Average target price

6,371 JPY

Spread / Average Target

+46.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NIPPON SHINYAKU CO., LTD.	-13.23%	1.85B
ELI LILLY AND COMPANY	+26.32%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.46%	352B
MERCK & CO., INC.	+18.81%	332B
ABBVIE INC.	+3.85%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.10%	145B

Other Pharmaceuticals